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Introduction. Basal insulin (BI) infusion in pump therapy of type 1 diabetes (T1DM) mimics physiological secretion during the night
and between meals. .e recommended percentage of the total BI to daily insulin dose (termed the %BI) ranges between 30 and 50%.
We analyzed whether this recommendation was followed in adults with T1DM from a university center, and whether BI doses were
linked with glycemic control. Materials and Methods. We included 260 consecutive patients with T1DM (159 women and 101 men)
treated with continuous subcutaneous insulin infusion at the Department of Metabolic Diseases, Krakow, Poland. Data were
downloaded from patients’ pumps and collected frommedical records. We analyzed the settings of BI and the association of %BI with
HbA1c level. Linear regressionwas performed.Results..emean age of T1DM individuals was 26.6±8.2 years, BMIwas 23.1±3.0 kg/m2,
T1DM duration was 13.3± 6.4 years, and HbA1c level was 7.4%. .ere were 69.6% (n � 181) of T1DM patients with %BI in the
recommended range. .e T1DM duration and HbA1c level of patients with a %BI <30% (n � 23) was 9.5 years and 6.4%,
respectively; for a %BI of 30–50%, it was 13.2 years and 7.4%; and for a %BI >50% (n � 56), it was 15.8 years and 7.8% (p< 0.001
for both three-group comparisons). Multiple regression identiﬁed %BI among independent predictors of the HbA1c level.
Conclusion. In this real-life analysis, the recommendations concerning %BI dosing were not followed by almost one-third of adult
T1DM patients. Low %BI was associated with better glycemic control; however, this requires further conﬁrmation.
1. Introduction
Continuous subcutaneous insulin infusion (CSII) therapy by
insulin pumps has become a widely used treatment in pa-
tients with type 1 diabetes mellitus (TIDM). CSII is currently
the most physiological method of insulin delivery available
[1]. .is mode of insulin therapy includes two components:
basal insulin (BI) infusion that mimics physiological hor-
mone secretion during the night and between meals, and
boluses of insulin substituting acute postprandial insulin
secretion [2]..e total BI dose is recommended to constitute
30–50% of the total daily insulin dose (DID) in all age groups
of individuals with T1DM (the percentage of the total BI to
daily insulin dose is termed here the %BI) [3–5]. One
algorithm that is commonly used in adults with T1DM
speciﬁcally suggests programming of BI as a half of the
DID [6]. However, whether these recommendations are
followed in real-life clinical practice and if %BI in adults
with T1DM treated with CSII aﬀects glycemic control have
not been assessed so far. .is is particularly intriguing in
light of the clinical observations that keeping the %BI
below 40% and encouraging the patient to bolus more
frequently might lead to improved glycemic control with
less weight gain [7].
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.e requirement for basal insulin varies throughout the
day in healthy individuals and patients with T1DM [8–10].
.e highest demand was reported in the morning (4:00–8:00
a.m.). .is is related to the increased secretion of hormones
(such as glucagon, adrenaline, and cortisol) that decrease
insulin sensitivity [10, 11]. .eir secretion results in a rise of
blood glucose level in the early morning in many patients
with T1DM, termed the dawn phenomenon. Daily ﬂuctu-
ations of insulin sensitivity are additionally inﬂuenced by
physical activity, meals, and stress [8]. Indeed, it is a com-
mon practice for the CSII initiation to use three to four
diﬀerent BI rates per day to respond to changes in insulin
sensitivity [12].
.e proper BI dosing is crucial for achieving glycemic
control [1, 13]. Some studies suggest that BI rate variability
might be associated with severe hypoglycemic episodes or
even with chronic diabetic complications [8, 14]. Moreover,
both daily basal insulin requirement and circadian proﬁle
have been shown to be age-speciﬁc in patients with T1DM
[15]. In addition, lower BI infusion was associated with
a decreased HbA1c level in pediatric patients with T1DM
[1, 13], although there are currently only limited data
conﬁrming this observation in adult patients. Similarly, the
diurnal BI rate proﬁle also remains insuﬃciently deﬁned in
adult patients with T1DM.
In this study, we analyzed whether the %BI recom-
mendation was followed in adult patients with T1DM from
a single university diabetes center, and whether BI settings
were linked with glycemic control. .e speciﬁc aims of this
observational, retrospective study were to assess BI infusion,
its daily patterns, and the association of %BI with HbA1c
level.
2. Materials and Methods
We included 260 consecutive adult patients with T1DM (159
women and 101 men) treated with CSII and remaining
under diabetes care of the Department of Metabolic Dis-
eases, a tertiary university reference center in Krakow,
Poland. We excluded individuals with proliferative reti-
nopathy, diabetic kidney disease stage III or higher, pregnant
women, and those using other antidiabetic agents as adjunct
diabetes therapy or steroids. BI proﬁles were determined and
veriﬁed at each clinical visit by certiﬁed diabetologists. Basal
proﬁle from a day directly preceding the patient’s visit was
used for the %BI analysis. Data regarding BI proﬁles, daily
basal insulin, DID, average glycemia from blood glucose
measurements, and average blood glucose measurements
per day from the last two weeks were downloaded from
dedicated software (CareLink Professional and Accu-Chek
360). Other collected variables were gender, age, type of
insulin analog, weight, body mass index (BMI), T1DM
duration, years on CSII, and the HbA1c level, which were all
retrieved from themedical record. For the purpose of further
analysis, we divided the study group according to their
achievement of the recommended glycemic goal: HbA1c
equal to or below 7.0%, or HbA1c above 7.0%.
We ﬁtted the univariate regression models to identify
signiﬁcant predictors ofHbA1c level among seven independent
clinical variables: %BI, gender, age, BMI, T1DM, years on CSII,
and average blood glucose measurements per day. Covariates
signiﬁcantly associated with HbA1c in univariate analysis were
included in the multivariate model. To determine the diﬀer-
ences between two groups, Student’s t-test or Mann–Whitney
U test was used; the Shapiro–Wilk test was used for the as-
sessment of normality. To determine the diﬀerences between
three groups, the ANOVA or Kruskal–Wallis test was used
accordingly. To assess if there was a signiﬁcant association
between two categorical variables, the chi-square test was used.
Statistical analyses were made in R statistical software version
3.4.1. .e reported values for the whole group are represented
as mean± standard deviation or the median and range.
3. Results
.e T1DM study group included 159 women (61.2%) and
101 men (38.8%). .e patients were using rapid-acting in-
sulin analogues in their personal insulin pumps including
lyspro (n � 75; 47.3%), aspart (n � 68; 42.7%), and glulisine
(n � 16; 10%). .e study individuals were on average 26.6±
8.2 years old, with a BMI of 23.1± 3.0 kg/m2, and a T1DM
duration of 13.3± 6.4 years. .ere were 69.6% (n � 181) of
T1DM patients with their %BI in the recommended range of
30–50% (mean proportion was 42.1%), while 8.8% (n � 23)
of patients had their %BI below and 21.6% (n � 56) were
above the recommended range. .e T1DM duration and
HbA1c level of patients with a %BI <30% was 9.5 years and
6.4%, respectively; for those with a %BI of 30–50%, it was
13.2 years and 7.4%; and for a %BI >50%, it was 15.8 years
and 7.8% (p< 0.001 for both comparisons between the three
groups). .e HbA1c level and T1DM duration for patients
with a %BI <30% were signiﬁcantly lower than the other
groups (post hoc for HbA1c: versus %BI 30–50% p � 0.002,
versus %BI >50% p< 0.001; for T1DM duration: versus %BI
30–50% p � 0.009, versus %BI >50% p< 0.001). .ere was
no statistical diﬀerence between the three abovementioned
groups with respect to gender, age, and BMI.
Patients with less than 30% of %BI were characterized
with higher total insulin requirement per kg than those with≥30%, 0.83 IU versus 0.7 IU/kg, respectively, p � 0.02. No
correlation was found between %BI and BMI (p � 0.88).
Patients with T1DM with optimal glycemic control
(HbA1c level ≤7%; n � 119) were using on average
0.68 IU/kg/day and 39.4% of %BI, while individuals with
HbA1c >7.0% (n � 141) were using 0.73 IU/kg/day and
44.5% of BI (p � 0.016 and p< 0.0000, resp.). .e two
subgroups additionally diﬀered with respect to age, DID,
average glycemia, and number of blood glucose measure-
ments per day. Detailed descriptive characteristics of the
study cohort are provided in Table 1.
.e absolute values of BI in the circadian distribution are
shown in Figure 1. We observed a bimodal pattern in the di-
urnal proﬁle, with two phases of lower BI rates: one in the early
part of the night (nadir of 0.77 IU/h between 0:00 and 1:00 a.m.)
and one in the middle of the day (nadir of 0.78 IU/h between
12:00 and 1:00 p.m.). We also identiﬁed the largest peak of the
insulin requirement between 5:00 and 6:00 a.m. (1.03 IU/h) and
another smaller one between 6:00 and 7:00 p.m. (0.84 IU/h).
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In the univariate analysis, an association between HbA1c
level (as a dependent variable) and age, %BI, years on CSII,
and average number of blood glucose measurements per day
was found. In a multiple regression analysis with HbA1c
level as a dependent variable, the same variables as men-
tioned above were independently correlated with HbA1c
level (Table 2).
4. Discussion
In this observational study, we report that a substantial
proportion of adults with T1DM remaining under the care of
the university clinic use a %BI that is outside the recom-
mended range. We also provide some evidence that lower
than widely advised %BI might be associated with better
glycemic control.
Choosing an optimal BI dose may help improve the
eectiveness of therapy in patients with T1DM on insulin
pumps. Most diabetes guidelines recommend that the BI rate
should be programmed in hourly intervals, according to the
patient’s circadian variation of insulin requirement [16] and
based on their individual fasting tests over a period of 6–10 h
[14]. ey also suggest that a %BI range of between 30%
and 50% should be used [1–5, 15, 17]. We found that while
Table 1: Study group characteristics and the comparison between T1DM patients with in-target HbA1c and above-target HbA1c are shown.
Variables
Whole group HbA1c ≤7% HbA1c >7%
p
Mean SD Median Range Mean SD Mean SD
Age (years) 26.6 8.2 24.0 18–69 27.9 8.9 25.6 7.3 0.006
Weight (kg) 67.8 12.3 67.0 43–140 66.1 10.8 69.3 13.3 0.062
BMI (kg/m2) 23.1 3.0 22.6 16.7–40.9 22.8 2.8 23.3 3.1 0.213
T1DM duration (years) 13.3 6.4 13.0 2–37 13.2 6.7 13.5 6.2 0.479
Duration of CSII use (years) 6.8 3.6 7.0 1–17 6.4 3.7 7.1 3.5 0.091
HbA1c (%) 7.4 1.2 7.2 5.16–11.7 — — — — —
%BI (%) 42.1 10.1 42.0 14–78 39.4 9.7 44.5 10.0 0.000
DID (IU) 47.8 15.7 45.5 9–110 44.7 15.3 50.5 15.7 0.002
DID/kg (IU/kg) 0.71 0.20 0.69 0.11–1.62 0.68 0.21 0.73 0.19 0.016
Average glycemia from glucose meter (mg/dl) 157.3 34.0 155.0 88–279 143.4 28.8 169.2 33.7 0.000
Number of glucometer measurements per day (n) 5.4 3.0 5.0 0.2–15.5 6.1 3.2 4.7 2.6 0.010
BMI, body mass index; DID, daily insulin dose; CSII, continuous subcutaneous insulin infusion; %BI, percentage of basal insulin; IU, insulin units.
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Figure 1: Circadian distribution of basal insulin in the whole study group.
Table 2: Results of the univariate and multivariate linear regression analysis with HbA1c as the dependent variable.
Variable
Univariate analysis Multivariate analysis
Estimate 95% CI p value Estimate p value
%BI (%) 0.03 (0.01, 0.04) <0.001 0.02 0.002
Gender (F) 0.14 (−0.14, 0.43) 0.327 — —
Age at examination (years) −0.03 (−0.04, −0.01) 0.001 −0.03 0.005
T1DM duration (years) 0.01 (−0.01, 0.03) 0.294 — —
Duration of CSII (years) 0.05 (0.01, 0.09) 0.016 0.04 0.042
BMI (kg/m2) 0.03 (−0.02, 0.07) 0.24 — —
Average number of blood glucose measurements per
day (n) −0.10 (−0.15, −0.05) <0.001 −0.06 0.007
BMI, body mass index; CI, con¢dence interval; CSII, continuous glucose insulin infusion; %BI, percentage of basal insulin.
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this recommendation on %BI was followed in more than
two-third of patients with T1DM, there was a substantial
proportion of individuals using a %BI outside the recom-
mended range.
Recent results from a Japanese population suggested that
to achieve HbA1c <7.5%, the %BI should be set lower, to
30% [17]. .is is also consistent with recent observational
data from a pediatric population, where a drop of 10% in
%BI resulted in a decrease of HbA1c by 0.22% across all %BI
ranges [1]. .ese data are in-line with our results, as patients
with T1DM using a %BI below 30% had their mean HbA1c
lower than the rest of the participants.
Due to the nonrandomized and retrospective nature of
this project, we cannot, however, claim that using a lower %
BI would improve glycemic control in T1DM. Of note, the
patients with a %BI below 30% had T1DM for a shorter
period of time, which suggests that their residual insulin
might have played a role in this association. However, the
results of the multiple linear analysis indicated that %BI was
an independent predictor of the HbA1c level. In fact, to-
gether with the number of daily glucose measurements and
age of T1DM individuals, the %BI showed the strongest
association with glycemic control. .erefore, in light of
earlier reports and our study results, a question concerning
a change of the current recommendation and lowering the
advised range of %BI seems justiﬁed.
Of interest, we have shown that individuals with <30 %BI
are characterized with higher total daily insulin requirement.
We can speculate that it may be due to the need of delivering
more correction boluses when being on less percentage of
basal insulin or more precise meal bolus estimation.
Finally, our data on the circadian ﬂuctuations of BI
requirement generally conﬁrmed earlier reports [8, 15, 18].
.erefore, four basal intervals with two peaks of the insulin
requirement seem to be appropriate for adult patients with
T1DM [12].
.is report has some limitations. First, this was an
observational study; thus, we cannot deﬁnitively prove any
causative relationships, as a randomized, controlled study
would be required for this purpose. Additionally, some
important clinical variables that could potentially inﬂuence
the results were not included in our analyses, for example,
diﬀerent types of boluses, omitted and additional boluses,
and meal content, among others. Furthermore, we did not
examine the residual insulin secretion capacity, for example,
by measuring endogenous C-peptide [19]. Finally, data re-
ported here were collected in a single reference diabetes
clinic in Poland; thus, the conclusions of this study cannot be
automatically extended to other centers.
5. Conclusion
In the real-life analysis from a diabetes university center, the
recommendations concerning the %BI dosing were not
followed by almost one-third of adult patients with T1DM
on insulin pumps. Moreover, we identiﬁed some evidence
for the association of low %BI with better glycemic control;
however, this observation requires further conﬁrmation in
a larger, randomized, controlled study.
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